Literature DB >> 32158330

A Single-institution Study on Predictors of Short-term Progression from Mild Cognitive Impairment in Parkinson's Disease to Parkinson's Disease with Dementia.

Yuki Tajiri1, Kenji Wada-Isoe1,2, Kenichiro Tanaka1, Tadashi Adachi1, Ritsuko Hanajima1, Kenji Nakashima3.   

Abstract

BACKGROUND: Patients with non-demented Parkinson's disease (PD) sometime have mild cognitive impairment (MCI), and mild cognitive impairment in Parkinson's disease (PD-MCI) may convert to Parkinson's disease with dementia (PDD) within several years. Cognitive impairment also occurs in the early stages of the disease, gradually progressing to lower quality of life and instrumental activities of daily living. It is important to elucidate the predictors of progression from PD-MCI to PDD via longitudinal studies.
METHODS: This was a single center, case-control study. We analysed data from 49 patients with PD-MCI diagnosed as level I using the Movement Disorder Society PD-MCI criteria at baseline who had completed 1.5 years of follow-up. We defined patients who progressed to PDD as patients with progressive PD-MCI and patients who did not progress to PDD as patients with non-progressive PD-MCI. Depression, apathy, sleep disorders, constipation, light-headedness, hallucinations, impulse control disorders (ICDs) and impulsive-compulsive behaviors (ICBs) at baseline were statistically analysed as predictors of progression.
RESULTS: Of the 49 PD-MCI patients, 33 did not convert to PDD (non-progressive PD-MCI), and 16 converted to PDD (progressive PD-MCI). The Mini-Mental State Examination (MMSE) score, light-headedness and ICDs were elucidated as predictors of progressive PD-MCI via a multivariate logistic regression model. The adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for each item were MMSE score, OR 0.324, 95% CI 0.119-0.882, P = 0.027; light-headedness, OR 27.665, 95% CI 2.263-338.185, P= 0.009; and ICDs, OR 53.451, 95% CI 2.298-291.085, P = 0.010.
CONCLUSION: Cognitive function, ICDs and light-headedness may be risk factors for the development of PDD in PD-MCI patients. ©2020 Tottori University Medical Press.

Entities:  

Keywords:  Parkinson’s disease; cognition; dementia; impulse control disorders; light-headedness

Year:  2020        PMID: 32158330      PMCID: PMC7028534          DOI: 10.33160/yam.2020.02.004

Source DB:  PubMed          Journal:  Yonago Acta Med        ISSN: 0513-5710            Impact factor:   1.641


  24 in total

Review 1.  MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI.

Authors:  Irene Litvan; Dag Aarsland; Charles H Adler; Jennifer G Goldman; Jaime Kulisevsky; Brit Mollenhauer; Maria C Rodriguez-Oroz; Alexander I Tröster; Daniel Weintraub
Journal:  Mov Disord       Date:  2011-06-09       Impact factor: 10.338

Review 2.  Cognitive decline in Parkinson disease.

Authors:  Dag Aarsland; Byron Creese; Marios Politis; K Ray Chaudhuri; Dominic H Ffytche; Daniel Weintraub; Clive Ballard
Journal:  Nat Rev Neurol       Date:  2017-03-03       Impact factor: 42.937

3.  Natural course of mild cognitive impairment in Parkinson disease: A 5-year population-based study.

Authors:  Kenn Freddy Pedersen; Jan Petter Larsen; Ole-Bjørn Tysnes; Guido Alves
Journal:  Neurology       Date:  2017-01-20       Impact factor: 9.910

4.  The MoCA: well-suited screen for cognitive impairment in Parkinson disease.

Authors:  J C Dalrymple-Alford; M R MacAskill; C T Nakas; L Livingston; C Graham; G P Crucian; T R Melzer; J Kirwan; R Keenan; S Wells; R J Porter; R Watts; T J Anderson
Journal:  Neurology       Date:  2010-11-09       Impact factor: 9.910

Review 5.  Diagnostic procedures for Parkinson's disease dementia: recommendations from the movement disorder society task force.

Authors:  Bruno Dubois; David Burn; Christopher Goetz; Dag Aarsland; Richard G Brown; Gerald A Broe; Dennis Dickson; Charles Duyckaerts; Jefferey Cummings; Serge Gauthier; Amos Korczyn; Andrew Lees; Richard Levy; Irene Litvan; Yoshikuni Mizuno; Ian G McKeith; C Warren Olanow; Werner Poewe; Cristina Sampaio; Eduardo Tolosa; Murat Emre
Journal:  Mov Disord       Date:  2007-12       Impact factor: 10.338

6.  Impulsive compulsive behaviors in Japanese Parkinson's disease patients and utility of the Japanese version of the Questionnaire for Impulsive-Compulsive Disorders in Parkinson's disease.

Authors:  Kenichiro Tanaka; Kenji Wada-Isoe; Satoko Nakashita; Mikie Yamamoto; Kenji Nakashima
Journal:  J Neurol Sci       Date:  2013-06-02       Impact factor: 3.181

7.  Validation of the Parkinson's disease sleep scale in Japanese patients: a comparison study using the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale and Polysomnography.

Authors:  Yusuke Uemura; Takashi Nomura; Yuichi Inoue; Mika Yamawaki; Kenichi Yasui; Kenji Nakashima
Journal:  J Neurol Sci       Date:  2009-10-04       Impact factor: 3.181

8.  Impulse Control Disorder in Parkinson's Disease: A Meta-Analysis of Cognitive, Affective, and Motivational Correlates.

Authors:  Alice Martini; Denise Dal Lago; Nicola M J Edelstyn; James A Grange; Stefano Tamburin
Journal:  Front Neurol       Date:  2018-08-28       Impact factor: 4.003

9.  Impact of Cognitive Profile on Impulse Control Disorders Presence and Severity in Parkinson's Disease.

Authors:  Alice Martini; Luca Weis; Eleonora Fiorenzato; Roberta Schifano; Valeria Cianci; Angelo Antonini; Roberta Biundo
Journal:  Front Neurol       Date:  2019-03-22       Impact factor: 4.003

Review 10.  'Under pressure': is there a link between orthostatic hypotension and cognitive impairment in α-synucleinopathies?

Authors:  Sean J Udow; Andrew D Robertson; Bradley J MacIntosh; Alberto J Espay; James B Rowe; Anthony E Lang; Mario Masellis
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-09-09       Impact factor: 10.154

View more
  1 in total

Review 1.  The influence of white matter hyperintensity on cognitive impairment in Parkinson's disease.

Authors:  Hailing Liu; Bin Deng; Fen Xie; Xiaohua Yang; Zhenchao Xie; Yonghua Chen; Zhi Yang; Xiyan Huang; Shuzhen Zhu; Qing Wang
Journal:  Ann Clin Transl Neurol       Date:  2021-07-26       Impact factor: 4.511

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.